Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ — Eisai Co., Ltd. (“Eisai”) and Shanghai Henlius Biotech, Inc. (“Henlius”) today announced the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license
